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Editorial
Prof. Lászlo´ Hársing’s prescient contribution to the
discovery of tubuloglomerular feedback mechanism
by studying renal glucose transport inhibitors
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Diabetes mellitus (DM) (Types 1 and 2) affects millions of people worldwide and exerts a
tremendous healthcare burden on societies throughout the world (9, 25, 35). DM is a major
risk factor for chronic kidney disease in the United States and is responsible for the majority
of end-stage renal failure patients on dialysis (1). It is estimated that 30% of patients
diagnosed with DM will develop diabetic nephropathy, which is characterized by mesangial
expansion, thickening of the glomerular basement membrane, glomerular sclerosis, and
microalbuminuria (8, 22, 30). This progresses into greater microalbuminuria and kidney
failure (8, 19). Although extensive studies have attempted to delineate the mechanisms
responsible for the development of end-stage renal disease, the hyperglycemia that is a
hallmark of both Type 1 (T1) and Type 2 (T2) DM is clearly associated with the development
of progressive renal disease. Thus, numerous therapeutic strategies have been developed
through the years to control blood glucose levels and maintain them close to the normal
levels. Among the more classical treatments, one more recent approach to reduce the plasma
glucose levels has been to block the renal tubular glucose transport mechanisms thus causing
more glucose to be excreted in the urine. Glucose reabsorption in the proximal tubule is
mediated by sodium glucose transporter 2 (SGLT2) and 1 (SGLT1) (21). In particular,
blockers of the luminal SGLT2 have proven to be the most promising agents (2, 3, 38, 39).
SGLT2 inhibitors are derivatives of the compound phlorizin, a naturally occurring compound
found in certain species of apple trees (7). Phlorizin is a glucoside, which binds to SGLT2 and
SGLT1, and prevents glucose entry by acting as a competitive inhibitor (39). Phlorizin has
been used in research to study the mechanisms of renal transport by blocking the proximal
reabsorption of glucose, sodium, and water (5, 14). Because it promotes glycosuria, phlorizin
was investigated for its potential as a treatment for diabetes. However, because it also
blocks SGLT1, it interferes with intestinal glucose reabsorption, causing gastrointestinal side
effects (2).
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The major drawback to phlorizin as a therapeutic agent stems from the fact that its
binding afﬁnity for SGLT2 is only approximately sixfold higher than that for SGLT1,
meaning, it has relatively low selectivity for SGLT2 (39). Accordingly, synthetic derivatives
of phlorizin were developed to increase the selectivity for SGLT2. Modern SGLT2 inhibitors
have a 300- to 1,200-fold higher selectivity for SGLT2 compared with SGLT1 (18, 38). This
reduces the side effects associated with phlorizin, making the drugs more valuable as
therapeutic agents. Thus, the development of SGLT2 inhibitors has led to marked improve-
ment in regulation of plasma glucose levels, as well as body weight and blood pressure,
especially in T2DM (4, 20, 37). Moreover, SGLT2 inhibition ameliorates glomerular
hyperﬁltration in DM (3, 36).
In view of these recent developments and utilization of the SGLT2 inhibitors for the
treatment of DM, it is appropriate to recognize the prescient contributions to our
understanding of the actions of glucose transport inhibitors on kidney function by Professor
Lászlo´ Hársing, a giant in the world of Hungarian renal physiology. Sixty years ago in
1957, Hársing published a paper on “Effect of Phlorizin and of Mercurial Diuretics on
Renal Hemodynamics” in the journal of Acta Physiologica Academiae Scientiarum
Hungaricae (14). In that study, he used phlorizin to inhibit glucose reabsorption in the
proximal tubule and thus cause an overload of volume and solute delivery to the macula
densa plaque located at the end of the ascending loop of Henle. This increased solute load to
the macula densa causing reductions in renal plasma ﬂow and glomerular ﬁltration rate
(GFR). Hársing explained the results by invoking the ability of the macula densa to sense an
increase in the ﬁlling pressure or solute load and, in turn, send impulses from the macula
densa to the afferent arterioles thus regulating renal blood ﬂow (RBF) and GRF through a
“tubuloglomerular equilibrium.” While such a feedback mechanism from the macula densa
to the glomerular vasculature had been postulated on the basis of morphological observa-
tions (6), this study provided the ﬁrst functional data to support the existence of such a
feedback mechanism. In addition to the study using phlorizin, Hársing simultaneously
published two additional papers using other approaches to evaluate the properties of
tubuloglomerular equilibrium (13, 15). Accordingly in 2017, we are commemorating his
prescient studies from 1957, 60 years since the publication of his papers (13–15).
Dr. Lászlo´ Hársing, a gold-graduate doctor and doctor of medicine, started his career as
a university lecturer at the Institute of Physiology of the University of Medicine in Budapest,
and progressed over 16 years to become Professor and Director of the Pathophysiology
Institute until his retirement. During his retirement, he continued working as a Scientiﬁc
Advisor for the Oral Biology Department until April 8, 1995, when he passed away at the
age of 75.
In 1944, Hársing earned a doctor of medicine degree from the Medical School of Péter
Pázmány Catholic University in Budapest, a preeminent medical school in Central Europe,
currently known as Semmelweis University. He began his professional activities and
research work under professors István Rusznyák, Pál Gömöri, and Péter Bálint of the
Department of Internal Medicine, and studied the pathomechanism of tubular azotemia. In
1950, he joined the Institute of Physiology, where his scientiﬁc work on the tubuloglo-
merular feedback mechanism, in which he ﬁrst described the renal functional speciﬁcity
of this basic feedback-regulating system, gained greater recognition both nationally and
internationally. His observations came to the forefront of nephrology research only 10–15
years later and many publications have dealt with this very phenomenon ever since. Like so
many other Hungarian scholars working at that time behind the “Iron Curtain” of Central
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and Eastern Europe, Hársing was not assisted by good luck regarding his discoveries. His
publications in the early 1950s featured in the International English-language ACTA
Conference provided only relatively low-key publicity and were left without appropriate
recognition from abroad.
It was a belated satisfaction that in the 70s, many comprehensive summaries of this
topic in publications and in congressional state-of-the-art lectures brought this story back to
light and correctly recognized the pioneering work of Hársing and thus contributed greatly
to his reputation acquired in the ﬁeld of nephrology. In 1957 using animal studies, Hársing
demonstrated that Goormaghtigh’s (6) assumption was right in that the juxtaglomerular
apparatus is involved in the regulation of GFR. In his studies, Hársing examined the effects
of diuretics and hypertonic solutions on dogs, which increased urine ﬂow, distal tubular
ﬂuid osmotic load, and solute concentration that led to the resulting changes in renal plasma
ﬂow and GFR (13–15). He dubbed the phenomenon “tubuloglomerular equilibrium,”
which is known today as the “tubuloglomerular feedback mechanism” a modiﬁed term
suggested by Thurau (33, 34).
According to his observations, when the macula densa senses an increased osmotic/
sodium load or pressure in the tubular ﬂuid passing in front of it, the sensory organ will start
a complicated feedback process, which causes the afferent arterioles to contract, thus
increasing the vascular resistance and reducing the renal plasma ﬂow and GFR, leading to a
restoration of the distal tubular osmotic/sodium concentration or pressure. Speciﬁcally, he
postulated that:
“It is possible that in osmotic diuresis associated with an increase in ﬁlling of the distal
tubule impulses coming from the macula densa play a role in the regulation of RBF and
GFR.” (14)
In essence, the system is a classic negative feedback controller (24). This study gained
greater recognition when the Tubuloglomerular Feedback Mechanism Symposium in
Washington, DC was introduced by recognizing Hársing’s seminal discoveries. Historically,
it is of interest that a breakthrough came when about 30 years later Rosivall Lászlo´ sent a
copy of Hársing’s article to about 50 laboratories in the world dealing with this very topic.
The following year, Navar opened the Tubuloglomerular Feedback Mechanism Symposium
in Washington as follows: “As Hársing et al., 1957, experimentally proved for the ﬁrst time
the existence of tubuloglomerular feedback mechanism in Budapest...”
In subsequent years, Hársing studied the functional and morphological organization and
the regulation of renal microcirculation with emphasis on methodological approaches and the
autoregulation of both the cortex and medulla (17, 26, 28, 29, 31, 32). He developed a new
method for measuring the distribution of blood ﬂow in the kidney, which led to a number of
fundamental observations made regarding the renal medullary circulation and the ability to
concentrate urine (10, 16, 27).
In 1955, Professor Hársing defended his PhD thesis. In 1969, he earned the degree of
DSc from the Hungarian Academy of Sciences, the highest academic recognition in the
Hungarian system and was appointed professor at the Institute of Physiology. Between 1974
and 1990, he was director of the Institute of Pathophysiology. In his new position, he formed
the Kidney and Circulatory Research Group with his closest colleagues and students,
following in his footsteps until this day by continuing the research projects initiated by
him. After 1978, his interest turned toward the exploration of the mechanisms of
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compensatory renal hypertrophy. He continued his scientiﬁc activities even in his retirement
serving in the Department of Oral Biology as a scientiﬁc consultant.
Throughout his career, Hársing published about 150 scientiﬁc papers, two thirds of
which were in English. In the last three decades of his life, he visited all major European and
overseas nephrology centers on demand and participated regularly in international physiol-
ogy, pathophysiology, and nephrology world congresses as an invited speaker, president, and
symposium organizer.
Professor Hársing dedicated himself to teaching at his university for 50 years and he
played a crucial and leading role in the development of modernized curriculums in
physiology and pathophysiology. He authored and edited seven undergraduate textbooks.
Generations of medical doctors and pharmacists have been studying from both his physio-
logical and pathophysiological textbooks along with a number of notes and textbook chapters
that he wrote. Hungarian medical students were introduced to the concept of tubuloglo-
merular feedback decades ahead of their peers around the world. His logically structured and
exquisitely delivered lectures live vividly in the memory of his students and disciples. Each
and every sentence of his lectures, carefully worded and well placed, is rhetorically
exemplary. His elaborate choice of words came as an especially gracious gift of destiny,
which he elevated to new heights in his constant search and never ending respect for quality.
Professor Hársing was a member of several national and international scientiﬁc
societies; he played a leading role in the International Union of Physiological Sciences
(IUPS). He was also a founding member of the International Society for Pathophysiology, a
member of the Hungarian National Committee of the IUPS and of the International Council
of Scientiﬁc Unions (ICSU). As president of the Hungarian Society of Laboratory Medicine
and board member of the Hungarian Society of Nephrology, he invested heavily in
developing these disciplines. However, his service, worthy of an entire lifetime, associates
him primarily with the Hungarian Physiological Society of which he became a member in
1948 and Secretary General between 1966 and 1982, then president from 1982 to 1990.
During this period, Hungarian physiological scientists of that era visited physiological world
Fig. 1. Prof. Dr. Hársing Lászlo´ with colleagues, faculty, and students during the 1980s. He is in the middle of the ﬁrst
row, on his left side Prof. Dr. Szollár Lajos, and on his right side Prof. Dr. Rosivall Lászlo´ (Picture from 80s)
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congresses in unprecedented high numbers thanks to his great efforts. Professor Hársing also
contributed to the World Federation of Physiological Society, which ﬁnally responded to an
invitation by the Hungarian Physiological Society dating back to the 1930s (subscribed by
Verzár, Beznák, Mansfeld, Szentgyörgyi, and others) by organizing the XXVIII Physiologi-
cal World Congress in 1980 that had over 6,000 foreign participants in Budapest and was
overseen and co-organized by Hársing. This Congress became a great international success,
and opened a vast series of major international events that has since become the norm, thus
increasing not only the popularity of the subject discipline itself but also giving a boost to
Hungary’s international reputation in the biomedical sciences. At that meeting, several
lectures and symposia were focused on the role of the macula densa in the regulation of renal
hemodynamics (11, 12, 23, 33).
In honoring Professor Hársing, we honor a great and outstanding representative of the
famous and well-established Hungarian nephrology elite. He gained profound international
recognition for organizing scientiﬁc studies and meetings. His contributions as lecturer and
educator to generations of medical doctors laid down the foundations of higher medical
education in theoretical subjects. He spent his entire life in the service of his beloved
university and was immensely respected by his family, colleagues, students, and friends as
well as by his national and international scientiﬁc colleagues. Figure 1 shows him with his
colleagues and students.
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